On September 15, 2026, the clinical trial registry listed an update for a study involving dulaglutide. The trial, titled "Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial," is registered under identifier NCT07820111. The study is a Phase 3 trial and its status was recorded as completed on this date. Dulaglutide is an approved compound, and this trial evaluated weekly GLP-1 receptor agonists in a comparative design across diabetic and non-diabetic patient groups.
No results data were included in this update. The record reflects only a change in trial status to completed, not the availability or content of any findings. Readers should not assume outcomes, efficacy, or safety conclusions based on this status update alone. Further detail on trial design, patient population, and eventual results, if posted, would appear in subsequent registry updates or associated publications.
This brief reports only the status change as recorded in the trial registry entry. For more background on dulaglutide, including its approved uses and general profile, see the compound overview.